Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct;74(10):966-73.
doi: 10.4088/JCP.12m08252.

Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial

Eric G Smith  1 , Kristina M Deligiannidis, Christine M Ulbricht, Chelsea S Landolin, Jayendra K Patel, Anthony J Rothschild
Affiliations
Randomized Controlled Trial

Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial

Eric G Smith et al. J Clin Psychiatry. 2013 Oct.

Abstract

Objective: Intravenous N-methyl-d-aspartate (NMDA) antagonists have shown promising results in rapidly ameliorating depression symptoms, but placebo-controlled trials of oral NMDA antagonists as monotherapy have not observed efficacy. We conducted a randomized, double-blind, placebo-controlled trial of the NMDA antagonist memantine as an augmentation treatment for patients with DSM-IV major depressive disorder.

Method: Adult outpatients with major depressive disorder and partial response or nonresponse to their current antidepressant (as indicated by a 17-item Hamilton Depression Rating Scale score of ≥ 16 at baseline) were randomized (from July 2006-December 2011) to add memantine (flexible dose 5-20 mg/d, with all memantine group participants reaching the dose of 20 mg/d) (n = 15) or placebo (n = 16) to their existing treatment for 8 weeks. The primary outcome, change in Montgomery-Asberg Depression Rating Score (MADRS), was evaluated with repeated-measures mixed effects models using last-observation-carried-forward methods. Secondary outcomes included other depression and anxiety rating scales, suicidal and delusional ideation, and other adverse effects.

Results: 84% of participants completed the trial, including 93% of participants receiving memantine. Participants receiving memantine did not show a statistically or clinically significant change in MADRS scores compared to placebo, either over the entire study (β = 0.133, favoring placebo, P = .74) or at study completion (week 8 mean [SD] MADRS score change = -7.13 [6.61] [memantine]; -7.25 [11.14] [placebo]; P = .97). A minimal to small effect size (comparing change to baseline variability) favoring placebo was observed (Cohen d = 0.19). Similarly, no substantial effect sizes favoring memantine nor statistically significant between-group differences were observed on secondary efficacy outcomes.

Conclusions: This trial did not detect significant statistical or effect size differences between memantine and placebo augmentation among nonresponders or poor responders to conventional antidepressants. While the small number of participants is a limitation, this study suggests memantine lacks substantial efficacy as an augmentation treatment for major depressive disorder.

Trial registration: ClinicalTrials.gov identifier: NCT00344682.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Screening, Randomization, and Disposition of Patients with Major Depressive Disorder Incompletely Responding to Antidepressant Therapy Randomly Assigned to Treatment Augmentation with Memantine or Placebo
FIGURE 2
FIGURE 2
Changes in Depression Rating Scale Scores for Patients with Major Depressive Disorder Assigned to Memantine or Placebo Augmentation of Antidepressant Treatment (LOCF). A. Montgomery-Asberg Depression Rating Scales (LOCF, primary outcome) B. Montgomery-Asberg Depression Rating Scales (No imputation [“Observed Case”]) C. Quick Inventory of Depressive Symptoms, Self-Rated
FIGURE 2
FIGURE 2
Changes in Depression Rating Scale Scores for Patients with Major Depressive Disorder Assigned to Memantine or Placebo Augmentation of Antidepressant Treatment (LOCF). A. Montgomery-Asberg Depression Rating Scales (LOCF, primary outcome) B. Montgomery-Asberg Depression Rating Scales (No imputation [“Observed Case”]) C. Quick Inventory of Depressive Symptoms, Self-Rated
FIGURE 2
FIGURE 2
Changes in Depression Rating Scale Scores for Patients with Major Depressive Disorder Assigned to Memantine or Placebo Augmentation of Antidepressant Treatment (LOCF). A. Montgomery-Asberg Depression Rating Scales (LOCF, primary outcome) B. Montgomery-Asberg Depression Rating Scales (No imputation [“Observed Case”]) C. Quick Inventory of Depressive Symptoms, Self-Rated
See this image and copyright information in PMC

References

    1. Zarate CA, Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. - PubMed
    1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. - PubMed
    1. Machado-Vieira R, Ibrahim L, Henter ID, et al. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav. 2012;100(4):678–687. - PMC - PubMed
    1. Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82. - PMC - PubMed
    1. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426–437. - PMC - PubMed

Publication types

MeSH terms

Associated data